• Molecular NameBevantolol
  • Synonym1-(3,4-Dimethoxyphenethylamino)-3-(m-tolyloxy)-2-propanol; Bevantololum [inn-latin]
  • Weight345.439
  • Drugbank_IDDB01295
  • ACS_NO59170-23-9
  • Show 3D model
  • LogP (experiment)3.0
  • LogP (predicted, AB/LogP v2.0)2.44
  • pka8.1
  • LogD (pH=7, predicted)1.35
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-0.98
  • LogSw (predicted, AB/LogsW2.0)4.24
  • Sw (mg/ml) (predicted, ACD/Labs)0.41
  • No.of HBond Donors2
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds10
  • TPSA59.95
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA drug which acts as both a beta blocker and a calcium channel blocker.
  • Absorption_valueN/A
  • Absorption (description)Bevantolol is virtually completely absorbed (>85%) and undergoes moderate first pass metabolism.
  • Caco_2N/A
  • Bioavailability57.0
  • Protein binding96.5
  • Volume of distribution (VD)1.5 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmIt is extensively metabolised to 4 metabolites; the principal metabolite makes up 16% of the dose and 3 minor metabolites in trace amounts.
  • Half life1.5~2 h
  • ExcretionIt is excreted in urine (72%) mostly as metabolites and small amounts of the unchanged drug (<10%). It is also excreted in faeces (approx. 12%).
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A